WATERTOWN, Mass.–(BUSINESS THREAD)–Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a clinical-stage biopharmaceutical company focused on sickle cell disease (SCD), prostate cancer and other rare hematological diseases and cancers, today announced that it will release second quarter 2022 financial results on Friday, August 5, 2022. Form management will host an investment community conference call at 8:00 a.m. Eastern Daylight Time (EDT) on August 5, 2022 to discuss these financial results and provide a business update.
Investors can participate in the call through the registration link here. Once registered, participants will receive a dial number and PIN to enter the event. A live webcast of the conference call will be available on the “News and Investors” section of Forma’s website at www.formatherapeutics.com.
About Forma Therapeutics
Forma Therapeutics is a clinical-stage biopharmaceutical company focused on the research, development and commercialization of novel therapeutics to transform the lives of patients with rare hematological diseases and cancers. Our pipeline is led by etavopivat, an investigational once-daily selective pyruvate kinase-R (PKR) activator designed to be a disease-modifying therapy with the potential to improve red blood cell (RBC) health and transform the lives of the people who live. with sickle cell anemia, thalassemia and lower risk MDS. Our R&D engine combines deep biology knowledge, chemistry expertise and clinical development capabilities to create drug candidates with differentiated mechanisms of action focused on indications with high unmet need. Our work has resulted in a broad proprietary portfolio of programs with the potential to provide profound patient benefit. For more information, visit www.FormaTherapeutics.com or follow us on Twitter @FORMAInc and LinkedIn.
[ad_2]
Source link
